Abstract
Brain derived neurotrophic factor (BDNF) is the most prevalent growth factor in the central nervous system (CNS). It is essential for the development of the CNS and for neuronal plasticity. Because BDNF plays a crucial role in development and plasticity of the brain, it is widely implicated in psychiatric diseases. This review provides a summary of clinical and preclinical evidence for the involvement of this ubiquitous growth factor in major depressive disorder, schizophrenia, addiction, Rett syndrome, as well as other psychiatric and neurodevelopmental diseases. In addition, the review includes a discussion of the role of BDNF in the mechanism of action of pharmacological therapies currently used to treat these diseases, such antidepressants and antipsychotics. The review also covers a critique of experimental therapies such as BDNF mimetics and discusses the value of BDNF as a target for future drug development.
Footnotes
This article is available online at http://pharmrev.aspetjournals.org.
- © 2012 by The American Society for Pharmacology and Experimental Therapeutics
PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
In this issue
Jump to section
- Article
- Abstract
- I. Introduction
- II. Major Depressive Disorder and Therapies
- III. Brain-Derived Neurotrophic Factor and Other Mood-Related Disorders
- IV. Schizophrenia
- V. Addiction
- VI. Neurodevelopmental Disorders
- VII. Brain-Derived Neurotrophic Factor and Eating Disorders
- VIII. Brain-Derived Neurotrophic Factor-Based Therapeutics
- IX. Conclusions and Future Directions
- Acknowledgments
- Authorship Contributions
- Footnotes
- References
- Figures & Data
- Info & Metrics
- eLetters